JoVE Logo

Iniciar sesión

7.11 : Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.

A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote glycine release, increasing chloride influx into postsynaptic neurons and reducing excitability.

GABA mimetics, such as baclofen, activate GABAB receptors, leading to hyperpolarization of neuronal membranes and reduced excitability. Baclofen suppresses the release of excitatory transmitters in the brain and spinal cord, suppressing sensory afferents, interneurons, and motor neurons.

Benzodiazepines like diazepam bind to the allosteric site of GABAA receptors and facilitate GABA's action in the CNS. Diazepam reduces spasticity, particularly in the spinal cord, but sedation can occur at doses required to reduce muscle tone.

Tags

Spasmolytic AgentsMuscle SpasmsSpasticityChemical ClassificationCentrally Acting Spasmolytics2 agonistTizanidine2 adrenoceptorsGlutamateGlycineChloride InfluxGABA MimeticsBaclofenGABAB ReceptorsHyperpolarizationBenzodiazepinesDiazepamGABAA ReceptorsCNS Sedation

Del capítulo 7:

article

Now Playing

7.11 : Spasmolytic Agents: Chemical Classification

Skeletal Muscle Relaxants

841 Vistas

article

7.1 : Unión neuromuscular y bloqueo

Skeletal Muscle Relaxants

2.7K Vistas

article

7.2 : Clasificación de los relajantes del músculo esquelético

Skeletal Muscle Relaxants

2.3K Vistas

article

7.3 : Bloqueadores neuromusculares no despolarizantes (competitivos): mecanismo de acción

Skeletal Muscle Relaxants

1.4K Vistas

article

7.4 : Bloqueadores neuromusculares no despolarizantes (competitivos): acciones farmacológicas

Skeletal Muscle Relaxants

375 Vistas

article

7.5 : Bloqueadores neuromusculares no despolarizantes (competitivos): farmacocinética

Skeletal Muscle Relaxants

423 Vistas

article

7.6 : Bloqueadores despolarizantes: mecanismo de acción

Skeletal Muscle Relaxants

1.1K Vistas

article

7.7 : Bloqueadores despolarizantes: farmacocinéticos

Skeletal Muscle Relaxants

297 Vistas

article

7.8 : Relajantes musculares de acción directa: Dantroleno y toxina botulínica

Skeletal Muscle Relaxants

634 Vistas

article

7.9 : Relajantes del músculo esquelético: efectos adversos

Skeletal Muscle Relaxants

322 Vistas

article

7.10 : Relajantes del músculo esquelético: usos terapéuticos

Skeletal Muscle Relaxants

445 Vistas

article

7.12 : Relajantes musculares de acción periférica y central: una comparación

Skeletal Muscle Relaxants

3.1K Vistas

article

7.13 : Relajantes musculares de acción central: usos terapéuticos

Skeletal Muscle Relaxants

596 Vistas

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados